Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OM-301
- Development stage
- Preclinical
- Lead developer
- OphtiMedRx
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
OM-301 is a potent small molecule compound developed by OphtiMed to protect retinal pigment epithelium (RPE) cells from senescence. By targeting cellular senescence in the RPE, OM-301 aims to halt the progression of dry age-related macular degeneration (Dry AMD) during its early to intermediate stages. Preclinical studies have validated its senescence-protective activity both in vivo and in vitro. The developer has completed key preclinical and Chemistry, Manufacturing, and Controls (CMC) activities and has successfully concluded a pre-IND meeting with the FDA, positioning the candidate for Phase I clinical trials.
02
Targets
MDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on OM-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OM-301.